Search

Search Constraints

You searched for: Author/Creator Prestileo, T.

Search Results

1. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. (February 2019)

2. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. Issue 1 (February 2018)

3. Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). Issue 1 (16th February 2017)

4. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study. Issue 7 (9th August 2017)

5. OC.07.1 DIRECT ACTING ANTIVIRALS AFTER SUCCESSFUL TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA IMPROVE SURVIVAL AND REDUCE HEPATIC DECOMPENSATION IN HCV-CIRRHOTIC PATIENTS. (25th March 2019)

6. PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT. (25th March 2019)

7. Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). Issue 1 (16th February 2017)

8. Screening and linkage to care of prisoners with HCV infection: the RESIST-HCV project. (October 2019)

9. Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database. (10th February 2016)